Fisher Scientific customers and collaborators can expect the firm to continue to make acquisitions to bolster its life sciences portfolio — particularly its reagent play — as it aims to capitalize on a strong cash position.

Over the past two years, Fisher has entered the RNAi and cell-screening markets through its purchases of Dharmacon and Cellomics, respectively (see BioCommerce Week 8/11/2005).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.